男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影
Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Merck to invest more in country, sharpen focus on R&D, local tie-ups

By LIU ZHIHUA | China Daily | Updated: 2024-07-30 09:30
Share
Share - WeChat
A view of Merck's booth during an expo in Shanghai last month. [Photo/China Daily]

Merck will continue to invest in China, which is not only the second-largest consumer market in the world but also has rising innovation capability, said a senior executive of the German science and technology company.

"China is a significant market for us, for looking at innovation to bring it outside China and bringing our innovation into China," said Peter Guenter, a member of the executive board and CEO of Healthcare at Merck.

"We have done a lot of investments in China. Our commitment to China is clear. We will continue to grow, and we will continue to invest in the country."

The executive is deeply impressed by the remarkable changes in China's pharmaceutical market as it has "developed incredibly over the last 10 to 20 years, transforming from a generic industry focused on small molecules to one driven by innovation".

China has become very strong in technological innovation, as reflected by its rapid progress and innovation in the field of antibody-drug conjugates, he said.

China's huge potential as a major innovation hub holds great promise for Merck to collaborate with local partners, including startups, biotech and biopharma firms, and research institutes, to drive innovation forward, said Guenter.

"At a certain point in time, China could be the country from which innovation comes, truly first. I think that's the next frontier for the Chinese R&D ecosystem, to continue being very, very good at perfecting technologies, but also going upstream to find a new molecule for a new disease."

Citing various dynamics behind China's growing innovation drive that include well-educated talent and enabling regulatory environment, the executive spoke particularly highly of the clinical development pace in China.

The speed, agility and quality of the Chinese investigators who conduct clinical trials are remarkable, he said, adding the massive number of patients with unmet medical needs also contributes to the speedy drug development pace in the country.

1 2 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 深州市| 曲麻莱县| 罗定市| 富源县| 丹江口市| 遂川县| 大厂| 河池市| 三江| 霍林郭勒市| 体育| 通化市| 淄博市| 达州市| 靖远县| 遂溪县| 安仁县| 武宣县| 东海县| 长岛县| 固安县| 财经| 信宜市| 遵化市| 米易县| 招远市| 黄平县| 威海市| 屯昌县| 兰坪| 温州市| 平舆县| 福泉市| 阜康市| 北川| 太原市| 磐安县| 万年县| 新巴尔虎左旗| 郓城县| 绥棱县| 出国| 临高县| 开封市| 科技| 聊城市| 交口县| 田东县| 土默特右旗| 元江| 运城市| 获嘉县| 喜德县| 东山县| 内黄县| 阳新县| 衡东县| 浦县| 增城市| 广州市| 宜昌市| 上饶县| 阳原县| 房山区| 华池县| 惠来县| 梓潼县| 霍林郭勒市| 海兴县| 商城县| 榆中县| 商都县| 建宁县| 泸州市| 永昌县| 曲阳县| 黑山县| 赤城县| 河东区| 疏勒县| 门头沟区| 辛集市|